NIK SMI1 is primarily used in research settings to study and inhibit the NF-kappaB-inducing kinase (NIK) pathway. This pathway plays a critical role in immune responses, inflammation, and cell survival. By targeting NIK, researchers can explore its implications in autoimmune diseases, cancer, and other conditions where this pathway is dysregulated. The compound is particularly valuable in preclinical studies to understand the mechanisms of NIK signaling and to evaluate potential therapeutic strategies for diseases associated with its overactivation. Its application is largely confined to laboratory experiments and drug discovery efforts.